Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix intermittent androgen deprivation in prostate cancer
NL-OMON38143Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Primary endpoint: Time to PSA greater than 4 ng/mL during first intermittent cycle. Started Jan 2009; status: active, not recruiting.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON38143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38143.